Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Pemazyre™ (pemigatinib) for the Treatment of Cholangiocarcinoma

Drug (Brand/Generic)

Pemazyre (pemigatinib)

Developer

Incyte Corporation

Product Description

Oral tablets

Therapy Class

Fibroblast growth factor receptor (FGFR) inhibitor

Current Indication

Cholangiocarcinoma

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top